tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Kazia Therapeutics Limited (KZIA)
NASDAQ:KZIA
US Market
KZIA
Kazia Therapeutics
RESEARCH TOOLSreports
Advertisement

Kazia Therapeutics (KZIA) Stock News & Sentiment

Compare
312 Followers
Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Developments and Regulatory Catalysts
Premium
Ratings
Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Developments and Regulatory Catalysts
3d ago
KZIA
Buy Rating for Kazia Therapeutics Driven by Strategic Drug Approval and Licensing Initiatives
Premium
Ratings
Buy Rating for Kazia Therapeutics Driven by Strategic Drug Approval and Licensing Initiatives
3d ago
KZIA
Strategic Advancements and Potential in Oncology: Kazia Therapeutics’ Buy Rating Driven by Novel PD-L1 Degrader and AI-Driven Paxalisib Development
Premium
Ratings
Strategic Advancements and Potential in Oncology: Kazia Therapeutics’ Buy Rating Driven by Novel PD-L1 Degrader and AI-Driven Paxalisib Development
20d ago
KZIA
Kazia Therapeutics Partners with QIMR Berghofer for Innovative PD-L1 Degrader Program
Premium
Company Announcements
Kazia Therapeutics Partners with QIMR Berghofer for Innovative PD-L1 Degrader Program
23d ago
6K
KZIA
Kazia Therapeutics Reports Significant Tumor Reduction in TNBC Patient with Paxalisib
Premium
Company Announcements
Kazia Therapeutics Reports Significant Tumor Reduction in TNBC Patient with Paxalisib
29d ago
6K
KZIA
Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Developments in Cancer Treatment
Premium
Ratings
Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Developments in Cancer Treatment
2M ago
KZIA
Kazia Therapeutics Achieves Breakthrough in Breast Cancer Treatment with Paxalisib
Premium
Company Announcements
Kazia Therapeutics Achieves Breakthrough in Breast Cancer Treatment with Paxalisib
2M ago
6K
KZIA
More KZIA News >

KZIA News on the Web

Kazia Targets FDA Type C Meeting as Overall Survival Data in GBM Suggests Pathway for Conditional Approval
Market Chameleon
Neutral
Kazia Therapeutics Expands Pipeline with First-in-Class PD-L1 Protein Degrader—NDL2 Aims to Overcome Immunotherapy Resistance
Market Chameleon
Neutral
Kazia Therapeutics Highlights 86% Tumor Reduction in Metastatic TNBC Patient After Three Weeks of Paxalisib Combination Therapy
Market Chameleon
Neutral
Kazia Therapeutics target adjusted to $13 from $2 at H.C. Wainwright
The Fly
Neutral
Kazia Therapeutics Initiates Phase 1b Trial of Paxalisib in Advanced Breast Cancer
TipRanks News
Neutral
Kazia Therapeutics Announces ADS Ratio Change to Maintain Nasdaq Compliance
TipRanks News
Neutral
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease
Yahoo Finance
Neutral
Kazia Therapeutics Highlights Ongoing Oncology Drug Development Progress
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
KZIA
Sector Average
Media Buzz
This Week1 articles
Weekly Average1 articles
News Sentiment
This Week50%
Sector Average56%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is KZIA’s Media Buzz Sentiment?
1 articles about KZIA were published this week. In an average week, 1 articles are published.
    What is KZIA’s weekly average amount of articles?
    In an average week, 1 articles about KZIA are published.
      What is KZIA’s News Sentiment?
      50% of articles about KZIA were positive this week, compared to its sector average of 56%.
        Healthcare Stocks that are Trending in the News
        RNAAvidity Biosciences
        UHSUniversal Health
        HCAHCA Healthcare
        SLPSimulations Plus
        BBIOBridgeBio Pharma
        Showing the stocks with the most bullish news sentiment over the past week

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing